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Targeting mitochondrial dysfunction in
amyotrophic lateral sclerosis: a systematic
review and meta-analysis
Arpan R. Mehta,1,2,3,4,5 Rachel Walters,2,3,4 Fergal M. Waldron,6 Suvankar Pal,2,3,4
Bhuvaneish T. Selvaraj,1,2,4 Malcolm R. Macleod,2,3,4 Giles E. Hardingham,1,4,7
Siddharthan Chandran1,2,3,4,8,9,10 and Jenna M. Gregory1,2,3,4,11
Interventions targeting mitochondrial dysfunction have the potential to extend survival in preclinical models of amyotrophic lateral
sclerosis. The aim of this systematic review was to assess the efﬁcacy of targeting mitochondria as a potential therapeutic target in
amyotrophic lateral sclerosis. Preclinical studies written in the English language were identiﬁed with no restrictions on publication
date from PubMed, Medline and EMBASE databases. All studies adopting interventions targeting mitochondria to treat amyo-
trophic lateral sclerosis in genetic or drug-induced organism models were considered for inclusion. A total of 76 studies were
included in the analysis. Survival data were extracted, and the meta-analysis was completed in RevMan 5 software. We show that
targeting mitochondrial dysfunction in amyotrophic lateral sclerosis results in a statistically signiﬁcant improvement in survival
(Z¼ 5.31; P< 0.00001). The timing of administration of the intervention appears to affect the improvement in survival, with the
greatest beneﬁt occurring for interventions given prior to disease onset. Interventions at other time points were not signiﬁcant, al-
though this is likely to be secondary to a lack of publications examining these timepoints. The quality score had no impact on efﬁ-
cacy, and publication bias revealed an overestimation of the effect size, owing to one outlier study; excluding this led to the recalcu-
lated effect size changing from 5.31 to 3.31 (P<0.00001). The extant preclinical literature indicates that targeting mitochondrial
dysfunction may prolong survival in amyotrophic lateral sclerosis, particularly if the intervention is administered early. A limitation
of current research is a signiﬁcant bias towards models based on superoxide dismutase 1, with uncertainty about generalisability to
amyotrophic lateral sclerosis with an underlying TAR DNA binding protein 43 proteinopathy. However, further mechanistic re-
search is clearly warranted in this ﬁeld.
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dismutase 1; pmn ¼ progressive motor neuronopathy; PRISMA ¼ Preferred Reporting Items For Systematic Reviews and Meta-
analyses; TDP-43¼TAR DNA binding protein 43; VCP¼ valosin containing protein
Introduction
Amyotrophic lateral sclerosis (ALS), a type of motor neu-
ron disease (MND), is a rapidly progressive, incurable
and fatal neurodegenerative disorder, characterized by
paralysis due to loss of upper and lower motor neurons
(Brown and Al-Chalabi, 2017). There is no cure for ALS
and only one globally licensed treatment (riluzole, first
approved in 1995) that prolongs survival by a modest 2–
3months (Bensimon et al., 1994; Miller et al., 2012).
The absence of effective disease modifying treatments,
notwithstanding the promise of emerging candidates such
as edaravone (Hardiman and van den Berg, 2017; The
Writing Group and Edaravone (MCI-186) ALS 19 Study
Group, 2017), highlights the need to address the unsuc-
cessful translation of preclinical findings to the clinic
(Mitsumoto et al., 2014). A key requirement of advanced
and accelerated drug discovery is that it must be
informed by up-to-date, systematic, structured and un-
biased analysis and review of the preclinical literature to
enable both preclinical hypothesis generation and devel-
opment of putative therapies for clinical trials.
ALS is associated with defects in energy metabolism
(Vandoorne et al., 2018) leading to weight loss, hyperme-
tabolism and hyperlipidaemia (Dupuis et al., 2011).
Mitochondria are unique organelles, crucial for the regu-
lation of metabolic pathways and cell survival. Through
the Krebs cycle and the process of oxidative phosphoryl-
ation, nutrients from food that have been transported
into a cell are converted into ATP, which is then used to
fuel essential cellular processes. Alongside this canonical
function of mitochondria, they also play a central role in
calcium homeostasis and the regulation of apoptosis
(Cozzolino and Carrı`, 2012). Patients with ALS have
dense clusters of mitochondria in the anterior horn of the
lumbar spinal cord (Sasaki and Iwata, 1996) and
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presynaptic mitochondrial swelling in their motor neurons
(Siklo´s et al., 1996). The cellular distribution of mito-
chondria is also affected, with the majority of mitochon-
dria in ALS neurons located in the soma and proximal
axon (Sasaki et al., 2007) and expression of Miro1, a
protein that facilitates mitochondrial transport, is reduced
in the spinal cord of ALS patients (Zhang et al., 2015).
Moreover, the total amount of mitochondrial DNA,
measured by Southern blot, is reduced in the spinal cord
from ALS patients (Wiedemann et al., 2002). Dovetailing
these changes, functional deficit has been demonstrated,
insofar as patients with ALS have decreased activity of
the electron transport chain complexes in spinal cord
mitochondria (Wiedemann et al., 2002) and the activity
of key mitochondrial enzymes is reduced (Borthwick
et al., 1999). Notably, edaravone’s mechanism of action
is thought to be via reducing oxidative stress.
Furthermore, an extensive human induced pluripotent
stem cell-based phenotypic screen of drugs using motor
neurons derived from sporadic and familial cases identi-
fied ropinirole, a dopamine D2 receptor agonist, as the
top candidate. Interestingly, its beneficial effect was
attributed to it rescuing mitochondrial dysfunction, rather
than its effects on dopamine signalling (Fujimori et al.,
2018). Finally, not only are there a plethora of ALS-caus-
ing mutations that have been identified that impact on
mitochondrial function (Smith et al., 2017), there is also
direct evidence that disruption of mitochondrial structure
and function contributes to the aetiology of ALS, owing
to the discovery of causative mutations in the gene
encoding the mitochondrial protein, CHCHD10, which is
localized to contact sites between the inner and outer
mitochondrial membrane (Bannwarth et al., 2014).
Against this background, the primary aim of this review
was to examine the animal model (preclinical) literature,
and to evaluate the therapeutic potential of modulating
mitochondrial pathways in ALS. The secondary aims
were to: (i) determine the influence of timing of mito-
chondrial-based intervention and (ii) perform a quality as-
sessment of the preclinical literature, including an
assessment for publication bias. We hypothesized that
interventions targeting mitochondrial dysfunction signifi-
cantly affect survival in preclinical models of ALS.
Materials and methods
The well-established framework of The Collaborative
Approach to Meta-Analysis and Review of Animal Data
from Experimental Studies (CAMARADES; www.camar
ades.info) was adopted in this study (Vesterinen et al.,
2014).
Search methods
Preclinical data written in the English language were
obtained, with no restrictions on publication date, from
three databases: PubMed, Medline and EMBASE. The
following search terms were used (search date: 21st
March 2018):
PubMed
((‘motor neuron disease’ OR ‘motor neuron’ OR ‘MND’
OR ‘ALS’ OR ‘amyotrophic lateral sclerosis’) AND
(‘mitochondria’) AND (‘mouse’ OR ‘mice’ OR ‘murine’
OR ‘rat’ OR ‘drosophila’ OR ‘fruit fly’ OR ‘c elegans’
OR ‘zebrafish’ OR ‘yeast’))
Medline
((‘motor neuron disease’ OR ‘motor neuron’ OR ‘MND’
OR ‘ALS’ OR ‘amyotrophic lateral sclerosis’) AND
(‘mitochondria’) AND (‘mouse’ OR ‘mice’ OR ‘murine’
OR ‘rat’ OR ‘drosophila’ OR ‘fruit fly’ OR ‘c elegans’
OR ‘zebrafish’ OR ‘yeast’))
EMBASE
((‘motor neuron disease’ OR ‘motor neuron’ OR ‘MND’
OR ‘ALS’ OR ‘amyotrophic lateral sclerosis’) AND
(‘mitochondria’) AND (‘mouse’ OR ‘mice’ OR ‘murine’
OR ‘rat’ OR ‘drosophila’ OR ‘fruit fly’ OR ‘c elegans’
OR ‘zebrafish’ OR ‘yeast’))
The references obtained from these searches were col-
lated and imported into Endnote X8, where duplicate
studies were removed and full-text articles were retrieved.
Eligibility criteria
Inclusion criteria
Analysis of the effects of a therapeutic intervention on
survival in an ALS disease model compared with a con-
trol group testing an intervention that targets mitochon-
dria, including studies conducted in genetic or drug-
induced models adopting the following model organisms:
mouse, rat, Drosophila, zebrafish (D. rerio), C. elegans
and yeast.
Noting that drugs can modulate multiple potential tar-
gets, and that the dogma of ‘single drug, single target’ is
overly simplistic, here, for an intervention that targets
mitochondria, we included any study stating an effect on
this pathway, whether as a primary target or otherwise
(Paolini et al., 2006; Hopkins, 2008; Saha et al., 2018).
This was primarily to limit bias, with the aim of being
comprehensive in our assessment of the literature. It is
likely that the different therapeutic interventions identified
would target multiple, potentially non-overlapping, path-
ways. The intention was that all interventions identified
would have mitochondrial pathways as a commonality
and, therefore, through meta-analysis of many such inter-
ventions, we would be able to identify a common thera-
peutic effect.
Exclusion criteria
We excluded: human trials, cell culture models, models
where induction involved a combination of transgenesis
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and toxin; studies without a control group, publications
or abstracts without potential for data extraction, and re-
view articles, letters and comments.
Screening
Screening for potentially relevant papers was completed
via the Systematic Review Facility online screening tool
(http://syrf.org.uk), a freely available, online systematic re-
view tool. The title and abstract of each paper were
screened by two independent reviewers against the eligi-
bility criteria, and, in cases where reviewer concordance
was <0.66, a third reviewer assessed the paper. The dis-
posal of literature based on these criteria is duly pre-
sented in a PRISMA (Preferred Reporting Items for
Systematic Reviews and Meta-Analyses) flowchart
(Liberati et al., 2009) and the included literature formed
the analysis set.
Data extraction
Our primary outcome measure was mortality. We
extracted data for the following categories: intervention;
efficacy demonstrated (statistically significant): Yes/No/
Equivalent; survival in treatment group; survival in con-
trol group; number of individuals in treatment group;
number of individuals in control group; timing of inter-
vention: (i) prior to symptom onset, (ii) at symptom
onset, (iii) after symptom onset and (iv) end-stage disease;
model used; quality score based on modified
CAMARADES criteria (Macleod et al., 2004), with one
point being given for each of the following (total score ¼
9): peer review publication, statement of temperature con-
trol, sample size calculation, appropriate control group
identified, random allocation to treatment, allocation con-
cealment, blinded assessment of outcome, compliance
with animal welfare regulations, statement of potential
conflict of interests.
Statistical analysis
Survival data extracted from the included papers were
included on a forest plot using the freely available
Review Manager software (RevMan Version 5.3;
Copenhagen: The Nordic Cochrane Centre, The
Cochrane Collaboration, 2014). Given the variety of
model organisms included in the analysis, we expressed
effect sizes for the primary outcome data (survival sum-
mary data) as odds ratios for survival (Egger et al.,
2001; Vesterinen et al., 2014). We calculated summary
estimates within RevMan software using a random effects
model, weighted by study size, via Hedges G statistic
(Hedges and Olkin, 1985) to account for bias from small
sample sizes. We reported statistical heterogeneity using
I2 values (Higgins and Thompson, 2002), where an I2 of
0% represents no observed heterogeneity and larger val-
ues represent increasing heterogeneity, and we used fun-
nel plotting to assess for the presence of publication bias.
Predefined subgroup analyses were then performed to
examine the effects of (i) timing of when the intervention
was administered (intervention administered prior to the
onset of symptoms, at symptom onset, after symptom
onset); (ii) the pathways that each intervention acted on;
(iii) the mode of delivery of the intervention; (iv) the tar-
get (cell-wide distribution or specific mitochondrial target-
ing); and (v) quality score, and the number of studies
showing efficacy were compared between groups using a
two-way ANOVA with Bonferroni correction for multiple
comparisons (and chi2 for Fig. 4B and D). Post hoc sam-
ple size calculation was performed on studies included in
the timing of intervention analysis. It was not possible to
calculate an incidence from the latter two time points
(after disease onset and end-stage disease); however, post
hoc calculation of power performed on the second time
point (intervention administered at disease onset) revealed
that there was only a 12% power to detect a difference,
confirming that there was an insufficient number of stud-
ies at this time point to make a definitive conclusion.
Power calculation was performed as detailed below, per-
formed on dichotomous outcomes using incidence of effi-
cacy in each group compared to the population incidence
(i.e. incidence in all studies).
Power ¼ U
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
N P1  P0ð Þ
2
P0  Q0ð Þ
s
 Z1  a
2ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
P1  Q1ð Þ
P0  Q0ð Þ
s
8>>><
>>>:
9>>>=
>>>;
Power ¼ U
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
537  0:75 0:764ð Þ
2
0:764  0:236ð Þ
s
 1:96ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
0:75  0:25ð Þ
0:764  0:236ð Þ
s
8>>><
>>>:
9>>>=
>>>;
Power ¼ U 1:173ð Þ ¼ 0:12 ¼ 12% power
Data availability statement
All data have been made available through
Supplementary material.
Results
Searches of PubMed, Medline and EMBASE yielded 2151
results. Following the removal of duplicates, 1519
remained. Of these 1519 studies, 1384 were excluded
during the screening process and the full texts for the
remaining 135 papers were obtained. During data extrac-
tion, a further 59 were excluded, owing to inappropriate
or missing data. Thus, a total of 76 studies were
included. Some studies assessed more than one pathway
and/or drug; thus, 89 data points from 76 papers were
included in the quantitative meta-analysis (Fig. 1;
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Supplementary Table 1). All the included studies adopted
a rodent animal model, with most studies carried out in
the SOD1 G93A mouse model (89%; Supplementary
Fig. 1A).
Meta-analysis reveals significant
improvement in survival when
targeting mitochondrial
dysfunction
Meta-analysis demonstrated that interventions targeting
mitochondria are significantly more effective than control
[test for overall effect estimate, Z¼ 5.31 (P< 0.00001);
Fig. 2]. Furthermore, an assessment of heterogeneity
resulted in an I2 value of 0%, demonstrating that there is
no statistical heterogeneity between the studies included;
thus, the result is a consistent finding. Having identified
that the majority of the studies were carried out in the
SOD1 mouse model, we also performed a post hoc sub-
group analysis, using a random effects model and weight-
ing as per Materials and methods section, on studies
implementing models other than the SOD1 mouse model,
including: the TAR DNA binding protein 43, wobbler,
pmn, and valosin containing protein mouse models.
Meta-analysis of these studies (n¼ 5) favoured treatment
(odds ratio ¼ 1.39, Z¼ 1.28, P¼ 0.2) but this did not
reach statistical significance (Supplementary Fig. 1B).
However, post hoc calculation revealed that there was in-
sufficient power to detect a difference, confirming that
there were insufficient studies to make a definitive
conclusion.
Records idenﬁed through 
database searching
(n = 2151)
Sc
re
en
in
g
In
clu
de
d
El
ig
ib
ili
ty
Id
en
ﬁ
ca
o
n
Records aer duplicates removed
(n = 1519)
Records screened
(n = 1519)
Records excluded
(n = 1384)
Full-text arcles assessed 
for eligibility
(n = 135)
Full-text arcles excluded, 
with reasons*
(n = 59)
Studies included in 
quantave synthesis 
(meta-analysis)
(n = 76)
Figure 1 PRISMA flowchart. PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flowchart indicating numbers
of studies at each stage of the review. *Studies were excluded based on the following reasons: (i) due to inappropriate data formatting (i.e. where
no useable data could be extracted); (ii) conference poster abstract with insufficient data; or (iii) inappropriately screened (i.e. where the study
did not meet inclusion/exclusion criteria). For full dataset, see Supplementary Table 1.
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Figure 2 Meta-analysis of 76 preclinical studies shows therapeutic potential for targeting mitochondrial pathways in ALS.
Forest plot showing the odds ratio and confidence intervals calculated from survival summary data from each study, weighted by study size.
Overall effect estimate is demonstrated (with 95% confidence intervals) as a black diamond at the bottom of the graph. Heterogeneity is
displayed as an I2 value. Results demonstrate an overall statistically significant effect favouring targeting of mitochondrial pathways in ALS.
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Early manipulation of mitochondrial
dysfunction results in improved
survival
Secondary subgroup analysis examining the influence of
timing of intervention on survival was conducted, group-
ing studies based on the time point at which the thera-
peutic intervention was administered (pre-symptom onset,
at symptom onset and after symptom onset). Meta-ana-
lysis of studies conducted prior to symptom onset
(Fig. 3A) revealed a statistically significant improvement
in survival compared to controls (test of overall effect
Z¼ 4.66, P< 0.00001) with an I2 value of 7%, indicat-
ing very little heterogeneity. However, when studies
assessed after symptom onset were examined, there was
no statistically significant improvement in survival, likely
to be because there is a paucity of studies conducted
examining these time points (Fig. 3B and C). Indeed,
when studies were assessed for their probability of effi-
cacy depending on whether the intervention was carried
out prior to symptom onset or after symptom onset (all
three time points, see Materials and methods section),
there was no statistically significant effect (P> 0.05;
Fig. 3D). Post hoc power calculations performed on the
first two time points (prior to symptom onset and at
symptom onset) revealed that we had 100% and 12%
power to detect a difference, respectively. It was not pos-
sible to calculate an incidence from the latter two time
points (after disease onset and end-stage disease), since
there were no negative studies reported in the small sam-
ples included; consequently, it was not possible to per-
form a post hoc power calculation. This analysis
therefore revealed that there was an insufficient number
of studies to make a definitive conclusion about the effi-
cacy of interventions that were administered at later time
points.
Subgroup analyses reveal no
difference in efficacy between
divergent pathways, putative target
or mode of delivery of intervention
Further subgroup analysis was performed to assess puta-
tive target pathways of the interventions tested in the
analysis set (Fig. 4A). We identified eight target path-
ways: (i) anti-oxidative stress; (ii) anti-apoptosis; (iii) anti-
inflammation; (iv) metabolism; (v) electron transport
chain; (vi) mitophagy/degradation; (vii) calcium buffering;
and (viii) excitotoxicity. Oxidative stress was the most
frequently targeted pathway out of all interventions tested
and there was no statistically significant difference in effi-
cacy between interventions (P¼ 0.08; Fig. 4A). Next, we
analysed whether interventions were directly targeting
mitochondria, or indirectly through a cell-wide distribu-
tion (Fig. 4B). Indeed, the majority of studies imple-
mented interventions with a cell-wide distribution (91%
of studies). 75% of studies with a cell-wide distribution
demonstrated efficacy, compared with 100% of mito-
chondrially targeted interventions, although this difference
did not reach statistical significance (P¼ 0.136), likely be-
cause of the small number of studies implementing mito-
chondrially targeted therapies. Finally, we assessed the
mode of delivery of interventions implemented in the ana-
lysis set (Fig. 4C). The most frequent mode of delivery
was that of pharmacological agents delivered via the oral
route, accounting for 64% of the studies included. The
probability of demonstrating efficacy was lowest in this
intervention category, with 71% of these studies showing
efficacy, compared with 89% in all the other routes com-
bined (Fig. 4D), although this difference did not reach
statistical significance (P¼ 0.08).
Publication bias significantly
overestimated the effect size
Funnel plot demonstrated publication bias (Fig. 5). An
outlier (lying more than two standard deviations from an
otherwise tightly distributed dataset) was noted in the
dataset (Fig. 5A). To investigate this further, the outlier
was disregarded in a post hoc analysis and the funnel
plot was accordingly replotted (Fig. 5B). The recalculated
effect size can now be seen to pass directly through the
cluster that was previously sitting to the left of the line;
thus, the effect size decreases from 5.31 to 3.31. Whilst
still statistically significant, this outlier is likely contribu-
ting to an overestimation of the estimated effect size of
mitochondrial interventions. Furthermore, a structured
quality assessment was performed on the included studies;
the majority of papers scored highly in certain categories,
for example: (i) peer-reviewed articles; (ii) identification
of appropriate control groups; and (iii) statements regard-
ing conflicts of interest. However, other important cate-
gories were not so well-represented. The most strikingly
absent criterion was the use of a sample size calculation
which, although one of the pivotal aspects of designing a
study, was used in only 2 out of 76 papers. Despite this,
two-way ANOVA showed that the quality of the research
did not significantly impact the efficacy of the interven-
tions being tested (Fig. 5C; Supplementary Table 1).
Discussion
In summary, the data show that there is likely to be po-
tential in targeting mitochondrial dysfunction in ALS (test
for overall effect Z¼ 5.31, P< 0.00001), with particular
strength for interventions administered prior to disease
onset (test for overall effect Z¼ 4.66, P< 0.00001).
These findings are promising, since they have the poten-
tial to form not only the basis of future treatments for
ALS, but they also encourage mechanistic study focused
on mitochondrial dysfunction, because of the inference
that this is likely to be an early, perhaps presymptomatic,
Targeting mitochondrial dysfunction in ALS BRAIN COMMUNICATIONS 2019: Page 7 of 14 | 7
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/article-abstract/1/1/fcz009/5544105 by The U
niversity of Edinburgh user on 24 Septem
ber 2019
pathological event. Before discussing the implications of
our findings, it is worth considering the strengths and
weaknesses of our approach, and the limitations of the
findings.
A major strength of our overview approach is that this
is the first explicit systematic review, meta-analysis and
structured quality assessment of the preclinical ALS litera-
ture examining the influence of interventions targeting
mitochondrial dysfunction on survival. Preclinical studies
underpin our understanding of disease mechanisms and
are crucial for testing interventions for safety and effi-
cacy. However, they come with the caveat that animal
studies are inherently heterogeneous—much more so than
a clinical trial (Vesterinen et al., 2014)—and so they are
useful only if heterogeneity and their impact on the effect
size are taken into consideration. Accordingly, our ap-
proach, combining systematic review and meta-analysis,
addresses this.
The main weakness stems from the eligibility criteria,
by virtue of the fact that studies not reporting alterations
in survival were excluded. Thus, following the screening
process, 135 studies were included in the meta-analysis.
However, only 76 of these studies investigated survival in
their models used and, therefore, 59 papers were auto-
matically excluded. It would be desirable to incorporate
alternative outcome measures (such as, for example,
motor neuron counts, molecular biomarkers, body mass,
rotarod performance, gait analysis and behavioural
A B
C
D
Figure 3 The majority of studies are conducted at early time points and show that with early interventions there is a
statistically significant improvement in survival. Forest plots showing the odds ratio and confidence intervals calculated from survival
summary data from each study, weighted by study size. Overall effect estimate is demonstrated (with 95% confidence intervals) as a black
diamond at the bottom of the graph. Heterogeneity is displayed as an I2 value. (A) Interventions delivered pre-symptom onset; (B) at symptom
onset and (C) after symptom onset. (D) Stacked frequency histogram illustrating the number of studies demonstrating efficacy (blue) as a
proportion of the total number of studies (remaining white bar), divided into categories depending on timing of administered intervention.
Results demonstrate an overall statistically significant effect favouring the targeting of mitochondrial pathways early in ALS (A); however, there is
no difference in likelihood of demonstrating efficacy depending on timing of intervention (D), implying that there are too few studies conducted
at later time points (two-way ANOVA, P > 0.05).
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outcomes) but they need to be fully characterized, quanti-
fied and reported in the model. Such outcomes have the
potential to translate into surrogates of quality of life
outcomes relevant to people with ALS and their
caregivers.
Study limitations
First, the approach to determine potential therapeutic
interventions was based on the identification of a state-
ment by the authors in the included papers that the inter-
vention targeted putative mitochondrial pathways. This
method was employed to limit bias and to identify as
comprehensive a dataset as possible, being cognizant that
most drugs will have multiple target pathways, and it
assumes that those identified will have mitochondrial tar-
geting as a commonality. Notably, no approach to identi-
fying such interventions is perfect, because of, sometimes
unknown or not reported, off-target effects of drugs. If
authors did not mention mitochondrial targeting in their
study, we were not able to include it in our analysis. An
example of this limitation would be studies examining
the effects of rapamycin. Rapamycin is a drug known
mostly for its effect on autophagy; however, rapamycin
has also been shown to have multiple targets, including
effects on mitochondrial dysfunction, primarily through
its role in mitophagy, cellular metabolism and apoptosis
(Garza-Lombo´ et al., 2018; Li et al., 2018; Johnson
et al., 2019). Thus, as a result of its divergent roles in
different molecular pathways, and our inclusion criteria
aimed at limiting bias, not all studies assessing the effect
of rapamycin will have been included—only those where
the authors explicitly mentioned a role in mitochondrial
pathways.
Second, we show that the overall quality of the studies
conducted in the preclinical field of mitochondrial dys-
function in ALS is poor. Using a modification of the
CAMARADES criteria (Macleod et al., 2004), an estab-
lished quality score for assessing overall methodological
quality of individual studies in the preclinical literature, a
structured quality assessment was performed for each
paper included in the meta-analysis. The majority of
A B
C D
Figure 4 Subgroup analyses reveal no difference in efficacy between divergent pathways, putative target or mode of delivery
of intervention. (A) Frequency of studies implementing therapeutic interventions that target the following pathways: AO, anti-oxidative stress;
AA, anti-apoptosis; MT, metabolism; AI, anti-inflammation; MD, mitophagy/degradation; ETC, electron transport chain; CB, calcium buffering; EX,
excitotoxicity. Each column shows studies demonstrating efficacy in blue and no efficacy in white. Two-way ANOVA shows no statistically
significant difference (P > 0.05). (B) Frequency of studies implementing interventions that specifically target mitochondria (MT) versus more
generic cell-wide distribution (CWD). Each column shows studies demonstrating efficacy in blue and no efficacy in white. Chi2 demonstrates no
statistically significant difference (P ¼ 0.14). (C). Frequency of the mode of delivery of study interventions: PO, pharmaceutical oral; PIP,
pharmaceutical intraperitoneal; PSC, pharmaceutical subcutaneous; PIV, pharmaceutical intravenous; CTS, cell transplant specific cell type
indicated; CTU, cell transplant no specific cell type indicated; PCNS, pharmaceutical directly administered to central nervous system; GA,
genetic intervention, all cells targeted; U, unknown/not stated. Each column shows studies demonstrating efficacy in blue and no efficacy in white.
Two-way ANOVA shows no statistically significant difference (P > 0.05). (D) Post hoc analysis performed to compare pharmaceutical oral (PO)
versus all other modes of delivery grouped together. Chi2 demonstrates no statistically significant difference (P ¼ 0.08).
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papers scored highly in certain categories, for example:
(i) peer-reviewed articles, (ii) identification of appropriate
control groups and (iii) statements regarding conflicts of
interest. However, other important categories were not so
well-represented. The most strikingly absent criterion was
the use of a sample size calculation which, although one
of the pivotal aspects of designing a study, was used in
only 2 out of 76 papers. Since it is impossible to study a
whole population, it is necessary to obtain a fully repre-
sentative sample using a sample size calculation. Without
it, a sample may be too small to detect a significant re-
sult, or too large, with consequent ethical and financial
implications. Furthermore, if riluzole, which has been
shown to have a limited, but significant, effect in pro-
longing survival in patients with ALS (Miller et al.,
2012), is used as a benchmark positive control compound
in the most widely published mouse model of ALS,
assuming a modest effect size (circa 1%), even studies of
n> 50 animals per cohort would be insufficiently pow-
ered to detect it (Scott et al., 2008). Given that the sam-
ple sizes in the studies included in the meta-analysis
ranged from 4 to 39 (median ¼ 13), it is likely that the
vast majority, if not all, of these were underpowered.
There was also a distinct lack of random allocation and
blinding in a large number of the studies, subjecting these
and their effect sizes to unknown and unnecessary bias.
An important initiative set out with the aim to replicate
several studies published in the preclinical domain in ALS
found that there was consistent overestimation of the true
effect size (Perrin, 2014). It is therefore possible that the
overall effect size calculated in our study may be over-
inflated, due to widespread overestimation of the effect
size in studies particularly predating 2010, when guide-
lines were drawn up (Ludolph et al., 2010).
Third, out of the 76 studies that were included in the
meta-analysis, 89% used SOD1 G93A transgenic mouse
models, where there is overexpression (usually 23 copies)
of human genomic mutant SOD1 (Gurney et al., 1994).
We encountered difficulties from the lack of reporting the
transgene copy number and death from non-ALS causes
in the studies incorporated in our review. Seventeen stud-
ies stated that they used the high copy number mouse
model; 2 studies stated that they used the low copy num-
ber mouse model and 50 (72% of the included studies)
did not state the model used. Both of these variables af-
fect the conclusions that one can reliably draw, given
A B
C
Figure 5 Publication bias results in overestimation of effect size. (A) Funnel plot showing each point as a study, plotted against the
effect size of that study (abscissa) and precision of that study (SE(log[OR]); ordinate). One study outlier was identified (highlighted by a blue
square), skewing the effect size significantly, resulting in an overestimation of the effect size. (B) Adjusted funnel plot demonstrating recalculated
effect size estimate of 3.31, cf. 5.31.(C) Frequency distribution illustrating that the structured quality score is not significant in determining
intervention efficacy (two-way ANOVA, P > 0.05).
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that it is well known that high copy number models
show faster disease progression and earlier death com-
pared with those adopting a low copy number mice
(Turner and Talbot, 2008), and these mice may have a
heightened susceptibility to infections and other non-ALS
related illnesses (Scott et al., 2008; van der Worp et al.,
2010). Although this transgenic mouse model was and
remains important to the understanding of disease mecha-
nisms (Van Damme et al., 2017), the over-representation
of studies using this model needs to be considered; fur-
thermore, whilst our subgroup analysis of non-SOD1
model studies revealed no significant difference in thera-
pies targeting mitochondrial pathways, there was an in-
sufficient number of studies to make a definitive
conclusion at this time. The SOD1 mutation accounts for
a minority (<2%) of ALS patients (Rosen et al., 1993)
and, importantly, SOD1 cases do not display the patho-
logical hallmark of ALS, namely TAR DNA binding pro-
tein 43 proteinopathy, that is found in >97% of ALS
cases (Neumann et al., 2006; Kwiatkowski et al., 2009).
Thus, SOD1 transgenic models are likely to recapitulate
only certain aspects of ALS (Joyce et al., 2011); notwith-
standing this, there is emerging evidence that misfolded
SOD1 protein is pathologically present in sporadic ALS
with no known genetic cause (Pare´ et al., 2018), and in
cases of ALS caused by mutations in known ALS genes
other than SOD1 (Forsberg et al., 2019), suggesting that
SOD1 biology may well be involved in ALS pathogenesis
in general. With respect to mitochondrial neurobiology,
aberrations in mitochondrial morphology, function, clear-
ance and transport have been observed in mutant SOD1
mice (Shi et al., 2010).
Finally, whilst there is substantial homology between
animal models and humans in terms of conserved genes,
organ systems and systemic physiology, there are also
many important differences. Indeed the mitochondrial
genome, a double-stranded closed-circular molecule, has
substantial homology between human and rodent species,
with 16 569 base pairs in humans and 16 301 base pairs
in the mouse (Wallace and Fan, 2009). However, there
are important functional differences at an organismal
level (Uhl and Warner, 2015), and in ageing (Demetrius,
2006) and metabolism (Svenson et al., 2007), including
fundamental differences in the production rate of reactive
oxygen species between mice and humans (Finkel and
Holbrook, 2000). A well-established manifestation of
such a difference relates to the influence of calorie restric-
tion on phenotypic measures of mitochondrial function.
Several preclinical studies have demonstrated, via calorie
restriction, a protective effect on survival, through the
upregulation of protective mitochondrial pathways associ-
ated with apoptosis, reduced reactive oxygen species and
an overall reduction in metabolic demand. Indeed, calorie
restriction has been shown to extend lifespan in many la-
boratory organisms and plays a preventative role in age-
ing and diseases, including diabetes and cardiovascular
diseases (Partridge and Brand, 2005; Fontana et al.,
2008; Piper et al., 2011). However, a large systematic re-
view and meta-analysis of dietary restriction in the ani-
mal model literature concluded that this is more likely to
be the result of adaption to laboratory conditions, rather
than evolutionary conservation (Nakagawa et al., 2012).
Indeed, evidence for translation of the protective effects
of calorie restriction to humans is poor (Phelan and
Rose, 2005). It is therefore possible that pathways identi-
fied through this review may demonstrate efficacy in ani-
mal models, but that their translation to human
therapeutics is limited, highlighting the need for further
evaluation in human-based models.
Putative molecular pathways
The most targeted pathway in the extant preclinical lit-
erature is the anti-oxidative stress pathway. However,
no pathway has been shown to be better than any
others and no intervention has been tested more than
three times, questioning the reproducibility of findings.
We suggest that this is likely to be in part as a result of
the research tools that have been used to detect putative
targets (such as the cleaved caspase 3 assay), rather
than pure specificity of the target per se. Some pathways
are under-represented, such as studies examining for
defects in the autophagic turnover of damaged mito-
chondria, termed mitophagy, despite their being recent
advances in tools to examine both mitophagy and mito-
chondrial architecture simultaneously in vivo, such as
mito-QC (McWilliams et al., 2016). There is also a pau-
city of literature specifically exploring the influence of
aberrant mitochondrial pathways in glia in vivo, includ-
ing their dynamics (Jackson and Robinson, 2018).
Interestingly, there were very few studies adopting inter-
ventions that were specifically targeted to the mitochon-
dria, for instance, through conjugation to the lipophilic
cation, triphenyl phosphonium (Zielonka et al., 2017),
with the majority of studies adopting interventions that
had a cell-wide distribution. The latter is a contributor
to the limited success of interventions, despite their
promising theoretical mechanism of action, because only
a fraction of the compound is taken up by the
mitochondria.
Mode of administration of
intervention
We show that oral administration was the most frequent
mode of intervention and there was a trend towards
greater efficacy in studies adopting other routes of admin-
istration. This most likely reflects the poor oral bioavail-
ability of oral medications and has been cited as a major
flaw in previously conducted clinical trials in the ALS
field (Mitsumoto et al., 2014), notwithstanding the diffi-
culties many patients face with swallowing, owing to
brainstem dysfunction (Brown and Al-Chalabi, 2017).
Targeting mitochondrial dysfunction in ALS BRAIN COMMUNICATIONS 2019: Page 11 of 14 | 11
D
ow
nloaded from
 https://academ
ic.oup.com
/braincom
m
s/article-abstract/1/1/fcz009/5544105 by The U
niversity of Edinburgh user on 24 Septem
ber 2019
Implications for future research
Through conducting this systematic review and meta-ana-
lysis, we conclude that targeting mitochondrial dysfunc-
tion in ALS is likely to hold therapeutic potential and
that further research should be carried out to delve into
the mechanisms underlying the deficit and to further in-
vestigate the optimal timing of intervention. There is
clearly a focus in the current literature on presympto-
matic treatment of animals, which makes these therapies
more difficult to translate to the clinic. Whilst genetic
testing could identify individuals with potential for pre-
symptomatic intervention, the majority of ALS cases are
not caused by a known genetic mutation. Furthermore,
there is no existing biomarker for the detection of early
disease states in these cases. We therefore recommend
that preclinical studies focus on interventions at or after
symptom onset to improve the translational potential of
these studies. We also recommend that preclinical re-
search should adopt a wide variety of models (Van
Damme et al., 2017; Lutz, 2018), particularly of muta-
tions accounting for the commoner causes of ALS, such
as the C9orf72 repeat expansion (DeJesus-Hernandez
et al., 2011; Renton et al., 2011). Each model must be
fully characterized and suitably powered, and a range of
outcome measures reported, in addition to survival, at
various time points, particularly later time points follow-
ing the onset of symptoms, when interventions are likely
to have the greatest translational benefit and where there
currently is a paucity of studies. Pharmacological com-
pounds ought to be mitochondrially targeted, with
thought given to identifying a suitable route of adminis-
tration that maximizes bioavailability, and coupled to a
more comprehensive examination of their effects on mul-
tiple mitochondrial signalling and molecular pathways.
Finally, technological advances in human induced pluri-
potent stem cells and gene editing offer unprecedented
opportunities to develop new experimental human mod-
els of monogenic neurological diseases (Sandoe and
Eggan, 2013). Human induced pluripotent stem cells
maximize human relevance, mechanistic insight and also
afford high throughput (Dolmetsch and Geschwind,
2011). They uniquely facilitate the study of the non-cell-
autonomous influences of mitochondrial gene transcrip-
tion, owing to the ability to co-culture mixed species-
derived neurons with human induced pluripotent stem
cell-derived astrocytes (for example) and the identifica-
tion of signalling pathways through in silico RNA
sequencing read sorting (Qiu et al., 2018). Human
induced pluripotent stem cells also permit the study of
live cells in assays examining disease mechanistic vulner-
ability and sufficiency, and, as such, we recommend
that researchers adopt them to focus on investigating per-
turbations in mitochondrial pathways, adhering to recent
published guidelines (Connolly et al., 2018), thereby
expanding the repertoire of ALS disease models.
Supplementary material
Supplementary material is available at Brain
Communications online.
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